Radu Tanasescu

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8273777/publications.pdf

Version: 2024-02-01

279487 168136 3,112 77 23 h-index citations papers

g-index 88 88 88 4523 docs citations times ranked citing authors all docs

53

#	Article	IF	Citations
1	Easy to interpret coordinate based meta-analysis of neuroimaging studies: Analysis of brain coordinates (ABC). Journal of Neuroscience Methods, 2022, 372, 109556.	1.3	4
2	Guilty by association? SARSâ€CoVâ€2 antibodies and myelin oligodendrocyte glycoprotein antibodyâ€associated disease. European Journal of Neurology, 2022, , .	1.7	1
3	Effects of substance P on human cerebral microvascular endothelial cell line hCMEC/D3 are mediated exclusively through a truncated NK-1 receptor and depend on cell confluence. Neuropeptides, 2022, 95, 102265.	0.9	1
4	Uncovering the underhanded: B-cell depletion therapies and severe viral infections – Commentary on â€~Fatal underhanded chronic enterovirus infection associated with anti-CD20 monotherapy for central nervous system demyelinating disease'. Multiple Sclerosis Journal, 2021, 27, 323-324.	1.4	0
5	Beta interferons as immunotherapy in multiple sclerosis: a new outlook on a classic drug during the COVID-19 pandemic. QJM - Monthly Journal of the Association of Physicians, 2021, 114, 691-697.	0.2	9
6	Neurological Disorders Associated With COVID-19 Hospital Admissions: Experience of a Single Tertiary Healthcare Center. Frontiers in Neurology, 2021, 12, 640017.	1.1	6
7	Experimental infection with the hookworm, Necator americanus, is associated with stable gut microbial diversity in human volunteers with relapsing multiple sclerosis. BMC Biology, 2021, 19, 74.	1.7	17
8	Guillain–Barré Syndrome Variant Occurring after <scp>SARSâ€CoVâ€2</scp> Vaccination. Annals of Neurology, 2021, 90, 315-318.	2.8	134
9	Age at onset predicts outcome in aquaporin-4-IgG positive neuromyelitis optica spectrum disorder from a United Kingdom population. Journal of the Neurological Sciences, 2021, 431, 120039.	0.3	5
10	Coordinate based meta-analysis of networks in neuroimaging studies. NeuroImage, 2020, 205, 116259.	2.1	6
11	MOG-lgG-associated demyelination: focus on atypical features, brain histopathology and concomitant autoimmunity. Journal of Neurology, 2020, 267, 359-368.	1.8	22
12	Comorbidity in multiple sclerosis: its temporal relationships with disease onset and dose effect on mortality. European Journal of Neurology, 2020, 27, 105-112.	1.7	26
13	A different response to cytomegalovirus (CMV) and Epstein–Barr virus (EBV) infection in UK people with multiple sclerosis (PwMS) compared to controls. Journal of Infection, 2020, 80, 320-325.	1.7	16
14	Increased IL-2 and Reduced TGF-Î ² Upon T-Cell Stimulation are Associated with GM-CSF Upregulation in Multiple Immune Cell Types in Multiple Sclerosis. Biomedicines, 2020, 8, 226.	1.4	6
15	An Absence of Epstein–Barr Virus Reactivation and Associations with Disease Activity in People with Multiple Sclerosis Undergoing Therapeutic Hookworm Vaccination. Vaccines, 2020, 8, 487.	2.1	2
16	Localised Grey Matter Atrophy in Multiple Sclerosis and Clinically Isolated Syndrome—A Coordinate-Based Meta-Analysis, Meta-Analysis of Networks, and Meta-Regression of Voxel-Based Morphometry Studies. Brain Sciences, 2020, 10, 798.	1.1	7
17	Hookworm Treatment for Relapsing Multiple Sclerosis. JAMA Neurology, 2020, 77, 1089.	4.5	39
18	Reduced Myelin Signal in Normal-appearing White Matter in Neuromyelitis Optica Measured by 7T Magnetic Resonance Imaging. Scientific Reports, 2019, 9, 14378.	1.6	13

#	Article	IF	CITATIONS
19	Coordinate based meta analysis of voxel based morphometry studies does not show evidence of specific grey matter loss in posttraumatic stress disorder. European Neuropsychopharmacology, 2019, 29, S287-S288.	0.3	O
20	Epilepsy and associated mortality in patients with multiple sclerosis. European Journal of Neurology, 2019, 26, 342.	1.7	16
21	Siponimod for the treatment of secondary progressive multiple sclerosis. Expert Opinion on Pharmacotherapy, 2019, 20, 143-150.	0.9	33
22	Granulocyte-Macrophage Colony-Stimulating Factor as a Therapeutic Target in Multiple Sclerosis. Neurology and Therapy, 2019, 8, 45-57.	1.4	20
23	Coordinate based meta-analysis does not show grey matter atrophy in narcolepsy. Neuroscience and Biobehavioral Reviews, 2019, 102, 427-429.	2.9	6
24	Primary versus Secondary Central Nervous System Melanoma: a Diagnostic Dilemma and Report of a Case. Medicina Moderna, 2019, 26, 35-39.	0.0	0
25	Recent developments in interferon-based therapies for multiple sclerosis. Expert Opinion on Biological Therapy, 2018, 18, 665-680.	1.4	21
26	Smoking Cessation and the Reduction of Disability Progression in Multiple Sclerosis: A Cohort Study. Nicotine and Tobacco Research, 2018, 20, 589-595.	1.4	32
27	Sevenâ€Tesla Magnetization Transfer Imaging to Detect Multiple Sclerosis White Matter Lesions. Journal of Neuroimaging, 2018, 28, 183-190.	1.0	10
28	The Soluble Form of Toll-Like Receptor 2 Is Elevated in Serum of Multiple Sclerosis Patients: A Novel Potential Disease Biomarker. Frontiers in Immunology, 2018, 9, 457.	2.2	36
29	Do Antiretroviral Drugs Protect From Multiple Sclerosis by Inhibiting Expression of MS-Associated Retrovirus?. Frontiers in Immunology, 2018, 9, 3092.	2.2	24
30	Coordinate based random effect size meta-analysis of neuroimaging studies. Neurolmage, 2017, 153, 293-306.	2.1	23
31	Human endogenous retroviruses and multiple sclerosis: Causation, association, or after-effect?. Multiple Sclerosis Journal, 2017, 23, 1050-1055.	1.4	15
32	Decreased interferon-β induced STAT-4 activation in immune cells and clinical outcome in multiple sclerosis. Acta Neurologica Scandinavica, 2017, 136, 233-238.	1.0	3
33	Innate immune regulation of autoimmunity in multiple sclerosis: Focus on the role of Toll-like receptor 2. Journal of Neuroimmunology, 2017, 304, 11-20.	1.1	37
34	Prevalence of a history of prior varicella/herpes zoster infection in multiple sclerosis. Journal of NeuroVirology, 2017, 23, 839-844.	1.0	17
35	Alcohol withdrawal syndrome: mechanisms, manifestations, and management. Acta Neurologica Scandinavica, 2017, 135, 4-16.	1.0	134
36	The association between human endogenous retroviruses and multiple sclerosis: A systematic review and meta-analysis. PLoS ONE, 2017, 12, e0172415.	1.1	77

#	Article	IF	CITATIONS
37	ANTI AQUAPORIN 4 POSITIVE NEUROMYELITIS OPTICA SPECTRUM DISORDER AND PRIMARY SJÃ−GREN SYNDROME FOLLOWING SUCCESSFUL THERAPY FOR CHRONIC HEPATITIS C – REPORT OF A CLINICAL CASE. Romanian Journal of Neurology/ Revista Romana De Neurologie, 2017, 16, 74-77.	0.1	0
38	MULTIPLE CEREBRAL MELANOMA METASTASES WITH UNKNOWN PRIMARY TUMOR LOCATION: A CASE REPORT. Romanian Journal of Neurology/ Revista Romana De Neurologie, 2017, 16, 175-178.	0.1	0
39	Intestinal Parasites and Immunomodulation in Neuroinflammatory Disease. , 2016, , 189-209.		0
40	Functional reorganisation in chronic pain and neural correlates of pain sensitisation: A coordinate based meta-analysis of 266 cutaneous pain fMRI studies. Neuroscience and Biobehavioral Reviews, 2016, 68, 120-133.	2.9	70
41	The future of multiple sclerosis treatments. Expert Review of Neurotherapeutics, 2016, 16, 1341-1356.	1.4	7
42	Status of diagnostic approaches to AQP4-IgG seronegative NMO and NMO/MS overlap syndromes. Journal of Neurology, 2016, 263, 140-149.	1.8	60
43	Mortality in multiple sclerosis: meta-analysis of standardised mortality ratios. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, 324-331.	0.9	95
44	A THREE-STEP EXAMINATION IN DIFFERENTIATING PERIPHERAL FROM CENTRAL VERTIGO. Romanian Journal of Neurology/ Revista Romana De Neurologie, 2016, 15, 52-54.	0.1	0
45	Granulocyte-macrophage colony-stimulating factor: Increased expression by immune cells of patients with multiple sclerosis. Journal of the Neurological Sciences, 2015, 357, e15.	0.3	0
46	Randomized phase 1b trial of MOR103, a human antibody to GM-CSF, in multiple sclerosis. Neurology: Neuroimmunology and NeuroInflammation, 2015, 2, e117.	3.1	86
47	Reciprocal Regulation of Substance P and IL-12/IL-23 and the Associated Cytokines, IFN \hat{I}^3 /IL-17: A Perspective on the Relevance of This Interaction to Multiple Sclerosis. Journal of Neurolmmune Pharmacology, 2015, 10, 457-467.	2.1	28
48	PEGylated IFNÎ 2 -1a in the treatment of multiple sclerosis. Expert Opinion on Biological Therapy, 2015, 15, 1077-1084.	1.4	10
49	Coordinate based meta-analysis does not show grey matter atrophy in narcolepsy. Neuroscience and Biobehavioral Reviews, 2015, 57, 297-298.	2.9	13
50	Effects of proâ€inflammatory cytokines on cannabinoid <scp>CB</scp> ₁ and <scp>CB</scp> ₂ receptors in immune cells. Acta Physiologica, 2015, 214, 63-74.	1.8	95
51	TLR2 - an innate immune checkpoint in multiple sclerosis. Oncotarget, 2015, 6, 35131-35132.	0.8	8
52	Coordinate Based Meta-Analysis of Functional Neuroimaging Data Using Activation Likelihood Estimation; Full Width Half Max and Group Comparisons. PLoS ONE, 2014, 9, e106735.	1.1	20
53	Pharmacokinetic evaluation of fingolimod for the treatment of multiple sclerosis. Expert Opinion on Drug Metabolism and Toxicology, 2014, 10, 621-630.	1.5	13
54	Helminth Therapy for MS. Current Topics in Behavioral Neurosciences, 2014, 26, 195-220.	0.8	15

#	Article	IF	Citations
55	Diagnostic modalities in multiple sclerosis: Perspectives in children. Biomedical Journal, 2014, 37, 50.	1.4	11
56	Advances in the treatment of relapsing - Remitting multiple sclerosis. Biomedical Journal, 2014, 37, 41.	1.4	25
57	Urinary tract infections in multiple sclerosis: under-diagnosed and under-treated? A clinical audit at a large University Hospital. American Journal of Clinical and Experimental Immunology, 2014, 3, 57-67.	0.2	27
58	Pharmacokinetic evaluation of nabiximols for the treatment of multiple sclerosis pain. Expert Opinion on Drug Metabolism and Toxicology, 2013, 9, 1219-1228.	1.5	9
59	The endocannabinoid system: a revolving plate in neuro-immune interaction in health and disease. Amino Acids, 2013, 45, 95-112.	1.2	13
60	Role of oral teriflunomide in the management of multiple sclerosis. Neuropsychiatric Disease and Treatment, 2013, 9, 539.	1.0	12
61	Coordinate Based Meta-Analysis of Functional Neuroimaging Data; False Discovery Control and Diagnostics. PLoS ONE, 2013, 8, e70143.	1.1	18
62	Neurotoxicity of immunosuppressive therapies in organ transplantation. MÃ $\!\!\!\mid$ dica, 2013, 8, 170-5.	0.4	18
63	The Effects of Cannabinoids on Immune Cells, Responses and Diseases., 2012,, 307-359.		0
64	A drug discovery case history of â€~delta-9-tetrahydrocannabinol, cannabidiol'. Expert Opinion on Drug Discovery, 2011, 6, 437-452.	2.5	6
65	Screening for tumours in paraneoplastic syndromes: report of an EFNS Task Force. European Journal of Neurology, 2011, 18, 19.	1.7	489
66	EFNS guidelines for diagnosis, therapy and prevention of Wernicke encephalopathy. European Journal of Neurology, 2010, 17, 1408-1418.	1.7	484
67	Cannabinoids and the immune system: An overview. Immunobiology, 2010, 215, 588-597.	0.8	209
68	Paraplegia due to non-osseous spinal tuberculosis: report of three cases and review of the literature. International Journal of Infectious Diseases, 2008, 12, 425-429.	1.5	41
69	Antiphospholipid antibodies and migraine: a retrospective study of 428 patients with inflammatory connective tissue diseases. Romanian Journal of Internal Medicine, 2007, 45, 355-63.	0.4	3
70	Prospective study of symptomatic atherothrombotic intracranial stenoses: The GESICA Study. Neurology, 2006, 66, 1187-1191.	1.5	289
71	Acute myeloid leukaemia induced by mitoxantrone in a multiple sclerosis patient. Journal of Neurology, 2004, 251, 762-3.	1.8	28
72	Vasopressin neurotransmission and the control of circadian rhythms in the suprachiasmatic nucleus. Progress in Brain Research, 1999, 119, 351-364.	0.9	67

#	Article	IF	CITATIONS
73	Wernicke's Encephalopathy. , 0, , .		1
74	Posttransplantation Encephalopaties., 0,,.		1
75	Central Nervous System Involvement in Lyme Disease - Making the Diagnosis and Choosing the Correct Treatment. , 0, , .		1
76	Atypical X-linked adult adrenoleukodystrophy with cerebellar and brainstem involvement - a case report. Endocrine Abstracts, 0 , , .	0.0	0
77	The Potential for EBV Vaccines to Prevent Multiple Sclerosis. Frontiers in Neurology, 0, 13, .	1.1	17